Header Logo

Connection

CHARLES WYKOFF to Prospective Studies

Back to Details
This is a "connection" page, showing publications CHARLES WYKOFF has written about Prospective Studies.
CHARLES WYKOFF
Connection Strength
1.686
Prospective Studies
  1. Final Outcomes from the Randomized RECOVERY Trial of Aflibercept for Retinal Nonperfusion in Proliferative Diabetic Retinopathy. Ophthalmol Retina. 2022 07; 6(7):557-566.
    View in: PubMed
    Score: 0.092
  2. Characterizing New-Onset Exudation in the Randomized Phase 2 FILLY Trial of Complement Inhibitor Pegcetacoplan for Geographic Atrophy. Ophthalmology. 2021 09; 128(9):1325-1336.
    View in: PubMed
    Score: 0.086
  3. Real-Time Photographic- and Fluorescein Angiographic-Guided Management of Diabetic Retinopathy: Randomized PRIME Trial Outcomes. Am J Ophthalmol. 2021 06; 226:126-136.
    View in: PubMed
    Score: 0.086
  4. Noncompliance in Prospective Retina Clinical Trials: Analysis of Factors Predicting Loss to Follow-up. Am J Ophthalmol. 2020 02; 210:86-96.
    View in: PubMed
    Score: 0.078
  5. Intravitreal Aflibercept for Retinal Nonperfusion in Proliferative Diabetic Retinopathy: Outcomes from the Randomized RECOVERY Trial. Ophthalmol Retina. 2019 12; 3(12):1076-1086.
    View in: PubMed
    Score: 0.077
  6. Suprachoroidal Space Alterations Following Delivery of Triamcinolone Acetonide: Post-Hoc Analysis of the Phase 1/2 HULK Study of Patients With Diabetic Macular Edema. Ophthalmic Surg Lasers Imaging Retina. 2018 09 01; 49(9):692-697.
    View in: PubMed
    Score: 0.072
  7. Longitudinal Quantification of Retinal Nonperfusion in the Macula of Eyes With Retinal Vein Occlusion Receiving Anti-VEGF Therapy: Secondary Analysis of the WAVE Randomized Trial. Ophthalmic Surg Lasers Imaging Retina. 2018 04 01; 49(4):258-264.
    View in: PubMed
    Score: 0.070
  8. Neovascular age-related macular degeneration management in the third year: final results from the TREX-AMD randomised trial. Br J Ophthalmol. 2018 04; 102(4):460-464.
    View in: PubMed
    Score: 0.067
  9. Relationship Between Visual Acuity and Retinal Thickness During Anti-Vascular Endothelial Growth Factor Therapy for Retinal Diseases. Am J Ophthalmol. 2017 Aug; 180:8-17.
    View in: PubMed
    Score: 0.066
  10. Peripheral Laser for Recalcitrant Macular Edema Owing to Retinal Vein Occlusion: The WAVE Trial. Ophthalmology. 2017 06; 124(6):919-921.
    View in: PubMed
    Score: 0.065
  11. Long-term Effects of Intravitreal 0.19 mg Fluocinolone Acetonide Implant on Progression and Regression of Diabetic Retinopathy. Ophthalmology. 2017 04; 124(4):440-449.
    View in: PubMed
    Score: 0.065
  12. Prospective Trial of Treat-and-Extend versus Monthly Dosing for Neovascular Age-Related Macular Degeneration: TREX-AMD 1-Year Results. Ophthalmology. 2015 Dec; 122(12):2514-22.
    View in: PubMed
    Score: 0.059
  13. Progressive retinal nonperfusion in ischemic central retinal vein occlusion. Retina. 2015 Jan; 35(1):43-7.
    View in: PubMed
    Score: 0.056
  14. Aflibercept treatment for patients with exudative age-related macular degeneration who were incomplete responders to multiple ranibizumab injections (TURF trial). Br J Ophthalmol. 2014 Jul; 98(7):951-5.
    View in: PubMed
    Score: 0.053
  15. SAVE (Super-dose anti-VEGF) trial: 2.0 mg ranibizumab for recalcitrant neovascular age-related macular degeneration: 1-year results. Ophthalmic Surg Lasers Imaging Retina. 2013 Mar-Apr; 44(2):121-6.
    View in: PubMed
    Score: 0.049
  16. Anti-VEGF Pharmaceutical Prior Authorization in Retina Practices. JAMA Ophthalmol. 2024 Aug 01; 142(8):716-721.
    View in: PubMed
    Score: 0.027
  17. Longitudinal Quantitative Ultrawidefield Angiographic Features in Diabetic Retinopathy Treated with Aflibercept from the Intravitreal Aflibercept as Indicated by Real-Time Objective Imaging to Achieve Diabetic Retinopathy Improvement Trial. Ophthalmol Retina. 2024 Feb; 8(2):116-125.
    View in: PubMed
    Score: 0.026
  18. Avacincaptad pegol for geographic atrophy secondary to age-related macular degeneration: 18-month findings from the GATHER1 trial. Eye (Lond). 2023 12; 37(17):3551-3557.
    View in: PubMed
    Score: 0.025
  19. Association of Predominantly Peripheral Lesions on Ultra-Widefield Imaging and the Risk of Diabetic Retinopathy Worsening Over Time. JAMA Ophthalmol. 2022 10 01; 140(10):946-954.
    View in: PubMed
    Score: 0.024
  20. Association of Ultra-Widefield Fluorescein Angiography-Identified Retinal Nonperfusion and the Risk of Diabetic Retinopathy Worsening Over Time. JAMA Ophthalmol. 2022 10 01; 140(10):936-945.
    View in: PubMed
    Score: 0.024
  21. NEW BIOMARKER QUANTIFYING THE EFFECT OF ANTI-VEGF THERAPY IN EYES WITH PROLIFERATIVE DIABETIC RETINOPATHY ON ULTRAWIDE FIELD FLUORESCEIN ANGIOGRAPHY: RECOVERY Study. Retina. 2022 03 01; 42(3):426-433.
    View in: PubMed
    Score: 0.023
  22. EFFECT OF RETINAL THICKNESS VARIABILITY ON VISUAL OUTCOMES AND FLUID PERSISTENCE IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION: A Post Hoc Analysis of the HAWK and HARRIER Studies. Retina. 2022 03 01; 42(3):511-518.
    View in: PubMed
    Score: 0.023
  23. Early Residual Fluid-Free Status and Long-Term BCVA Outcomes: A Treatment Agnostic, Post Hoc Analysis of Pooled HAWK and HARRIER Data. Am J Ophthalmol. 2022 04; 236:12-19.
    View in: PubMed
    Score: 0.023
  24. Exploring the angiographic-biologic phenotype in the IMAGINE study: quantitative UWFA and cytokine expression. Br J Ophthalmol. 2022 10; 106(10):1444-1449.
    View in: PubMed
    Score: 0.022
  25. Retinal vascular bed area on ultra-wide field fluorescein angiography indicates the severity of diabetic retinopathy. Br J Ophthalmol. 2022 08; 106(8):1126-1131.
    View in: PubMed
    Score: 0.022
  26. RETINAL LEAKAGE INDEX DYNAMICS ON ULTRA-WIDEFIELD FLUORESCEIN ANGIOGRAPHY IN EYES TREATED WITH INTRAVITREAL AFLIBERCEPT FOR PROLIFERATIVE DIABETIC RETINOPATHY IN THE RECOVERY STUDY. Retina. 2020 Nov; 40(11):2175-2183.
    View in: PubMed
    Score: 0.021
  27. Automated vessel density detection in fluorescein angiography images correlates with vision in proliferative diabetic retinopathy. PLoS One. 2020; 15(9):e0238958.
    View in: PubMed
    Score: 0.021
  28. Effect of Aflibercept on Diabetic Retinopathy Severity and Visual Function in the RECOVERY Study for Proliferative Diabetic Retinopathy. Ophthalmol Retina. 2021 05; 5(5):409-419.
    View in: PubMed
    Score: 0.021
  29. Longitudinal panretinal microaneurysm dynamics on ultra-widefield fluorescein angiography in eyes treated with intravitreal aflibercept for proliferative diabetic retinopathy in the recovery study. Br J Ophthalmol. 2021 08; 105(8):1111-1115.
    View in: PubMed
    Score: 0.021
  30. Suprachoroidal CLS-TA plus Intravitreal Aflibercept for Diabetic Macular Edema: A Randomized, Double-Masked, Parallel-Design, Controlled Study. Ophthalmol Retina. 2021 01; 5(1):60-70.
    View in: PubMed
    Score: 0.021
  31. SEVERITY OF DIABETIC MACULAR EDEMA CORRELATES WITH RETINAL VASCULAR BED AREA ON ULTRA-WIDE FIELD FLUORESCEIN ANGIOGRAPHY: DAVE Study. Retina. 2020 Jun; 40(6):1029-1037.
    View in: PubMed
    Score: 0.020
  32. Natural History of Geographic Atrophy Secondary to Age-Related Macular Degeneration: Results from the Prospective Proxima A and B Clinical Trials. Ophthalmology. 2020 06; 127(6):769-783.
    View in: PubMed
    Score: 0.020
  33. Relationship Between Retinal Fractal Dimension and Nonperfusion in Diabetic Retinopathy on Ultrawide-Field Fluorescein Angiography. Am J Ophthalmol. 2020 01; 209:99-106.
    View in: PubMed
    Score: 0.019
  34. Complement C3 Inhibitor Pegcetacoplan for Geographic Atrophy Secondary to Age-Related Macular Degeneration: A Randomized Phase 2 Trial. Ophthalmology. 2020 02; 127(2):186-195.
    View in: PubMed
    Score: 0.019
  35. Distribution of Nonperfusion and Neovascularization on Ultrawide-Field Fluorescein Angiography in Proliferative Diabetic Retinopathy (RECOVERY Study): Report 1. Am J Ophthalmol. 2019 10; 206:154-160.
    View in: PubMed
    Score: 0.019
  36. Classification of Regions of Nonperfusion on Ultra-widefield Fluorescein Angiography in Patients with Diabetic Macular Edema. Am J Ophthalmol. 2019 10; 206:74-81.
    View in: PubMed
    Score: 0.019
  37. Randomized Trial of Treat and Extend Ranibizumab With and Without Navigated Laser Versus Monthly Dosing for Diabetic Macular Edema: TREX-DME 2-Year Outcomes. Am J Ophthalmol. 2019 06; 202:91-99.
    View in: PubMed
    Score: 0.019
  38. Comparison of Early Treatment Diabetic Retinopathy Study Standard 7-Field Imaging With Ultrawide-Field Imaging for Determining Severity of Diabetic Retinopathy. JAMA Ophthalmol. 2019 01 01; 137(1):65-73.
    View in: PubMed
    Score: 0.019
  39. Ultra-Wide-Field Fluorescein Angiography-Guided Normalization of Ischemic Index Calculation in Eyes With Retinal Vein Occlusion. Invest Ophthalmol Vis Sci. 2018 07 02; 59(8):3278-3285.
    View in: PubMed
    Score: 0.018
  40. Topographic Correspondence of Macular Atrophy With Choroidal Neovascularization in Ranibizumab-treated Eyes of the TREX-AMD Trial. Am J Ophthalmol. 2018 08; 192:84-90.
    View in: PubMed
    Score: 0.018
  41. Changes in retinal ischaemic index correlate with recalcitrant macular oedema in retinal vein occlusion: WAVE study. Br J Ophthalmol. 2018 08; 102(8):1066-1071.
    View in: PubMed
    Score: 0.018
  42. Targeted Retinal Photocoagulation for Diabetic Macular Edema with Peripheral Retinal Nonperfusion: Three-Year Randomized DAVE Trial. Ophthalmology. 2018 05; 125(5):683-690.
    View in: PubMed
    Score: 0.017
  43. Distribution of Nonperfusion Area on Ultra-widefield Fluorescein Angiography in Eyes With Diabetic Macular Edema: DAVE Study. Am J Ophthalmol. 2017 Aug; 180:110-116.
    View in: PubMed
    Score: 0.017
  44. Macular Atrophy in Neovascular Age-Related Macular Degeneration with Monthly versus Treat-and-Extend Ranibizumab: Findings from the TREX-AMD Trial. Ophthalmology. 2017 02; 124(2):215-223.
    View in: PubMed
    Score: 0.016
  45. Randomized Trial of Treat and Extend Ranibizumab with and without Navigated Laser for Diabetic Macular Edema: TREX-DME 1 Year Outcomes. Ophthalmology. 2017 01; 124(1):74-81.
    View in: PubMed
    Score: 0.016
  46. Ranibizumab in preproliferative (ischemic) central retinal vein occlusion: the rubeosis anti-VEGF (RAVE) trial. Retina. 2014 Sep; 34(9):1728-35.
    View in: PubMed
    Score: 0.014
  47. Comparison of spectral-domain and time-domain optical coherence tomography in the detection of neovascular age-related macular degeneration activity. Retina. 2014 Jan; 34(1):48-54.
    View in: PubMed
    Score: 0.013
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.